130 related articles for article (PubMed ID: 32917727)
1. Noncanonical IL6 Signaling-Mediated Activation of YAP Regulates Cell Migration and Invasion in Ovarian Clear Cell Cancer.
Azar WJ; Christie EL; Mitchell C; Liu DS; Au-Yeung G; Bowtell DDL
Cancer Res; 2020 Nov; 80(22):4960-4971. PubMed ID: 32917727
[TBL] [Abstract][Full Text] [Related]
2. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
Anglesio MS; George J; Kulbe H; Friedlander M; Rischin D; Lemech C; Power J; Coward J; Cowin PA; House CM; Chakravarty P; Gorringe KL; Campbell IG; ; Okamoto A; Birrer MJ; Huntsman DG; de Fazio A; Kalloger SE; Balkwill F; Gilks CB; Bowtell DD
Clin Cancer Res; 2011 Apr; 17(8):2538-48. PubMed ID: 21343371
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
4. [Clinical features and drug resistance characteristics of ovarian clear cell adenocarcinoma and analysis of its prognostic factors].
Zhang CY; Guo HY; Li H; Wen HW; Liang XD; Qiao J
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):688-91. PubMed ID: 23159083
[TBL] [Abstract][Full Text] [Related]
5. HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival.
Li B; Jin H; Yu Y; Gu C; Zhou X; Zhao N; Feng Y
Int J Gynecol Cancer; 2009 Nov; 19(8):1347-52. PubMed ID: 20009888
[TBL] [Abstract][Full Text] [Related]
6. IL6-induced metastasis modulators p-STAT3, MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in ovarian cancer cells.
Zou M; Zhang X; Xu C
Cell Oncol (Dordr); 2016 Feb; 39(1):47-57. PubMed ID: 26510945
[TBL] [Abstract][Full Text] [Related]
7. Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation.
Shinjo K; Yamashita Y; Yamamoto E; Akatsuka S; Uno N; Kamiya A; Niimi K; Sakaguchi Y; Nagasaka T; Takahashi T; Shibata K; Kajiyama H; Kikkawa F; Toyokuni S
Int J Cancer; 2014 Jul; 135(2):308-18. PubMed ID: 24375438
[TBL] [Abstract][Full Text] [Related]
8. Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer.
Milagre CS; Gopinathan G; Everitt G; Thompson RG; Kulbe H; Zhong H; Hollingsworth RE; Grose R; Bowtell DD; Hochhauser D; Balkwill FR
Cancer Res; 2015 Apr; 75(7):1255-64. PubMed ID: 25670170
[TBL] [Abstract][Full Text] [Related]
9. Lysophosphatidic Acid and IL-6 Trans-signaling Interact via YAP/TAZ and STAT3 Signaling Pathways in Human Trabecular Meshwork Cells.
Yemanyi F; Raghunathan V
Invest Ophthalmol Vis Sci; 2020 Nov; 61(13):29. PubMed ID: 33216119
[TBL] [Abstract][Full Text] [Related]
10. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer.
Okuda T; Otsuka J; Sekizawa A; Saito H; Makino R; Kushima M; Farina A; Kuwano Y; Okai T
Gynecol Oncol; 2003 Mar; 88(3):318-25. PubMed ID: 12648581
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 receptor enhances early colonization of the murine omentum by upregulation of a mannose family receptor, LY75, in ovarian tumor cells.
Giridhar PV; Funk HM; Gallo CA; Porollo A; Mercer CA; Plas DR; Drew AF
Clin Exp Metastasis; 2011 Dec; 28(8):887-97. PubMed ID: 21887537
[TBL] [Abstract][Full Text] [Related]
12. FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.
Fan Q; Cai Q; Xu Y
Oncotarget; 2015 Sep; 6(29):27688-99. PubMed ID: 26299613
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma.
Ho CM; Lai HC; Huang SH; Chien TY; Lin MC; Chang SF
Eur J Clin Invest; 2010 Apr; 40(4):310-8. PubMed ID: 20486992
[TBL] [Abstract][Full Text] [Related]
14. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.
Kim HJ; Yoon A; Ryu JY; Cho YJ; Choi JJ; Song SY; Bang H; Lee JS; Cho WC; Choi CH; Lee JW; Kim BG; Bae DS
Sci Rep; 2016 Dec; 6():38502. PubMed ID: 27917934
[TBL] [Abstract][Full Text] [Related]
15. Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer.
Nakamura H; Nagasaka K; Kawana K; Taguchi A; Uehara Y; Yoshida M; Sato M; Nishida H; Fujimoto A; Inoue T; Adachi K; Nagamatsu T; Arimoto T; Oda K; Osuga Y; Fujii T
BMC Cancer; 2016 Nov; 16(1):897. PubMed ID: 27855669
[TBL] [Abstract][Full Text] [Related]
16. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
Bixel K; Saini U; Kumar Bid H; Fowler J; Riley M; Wanner R; Deepa Priya Dorayappan K; Rajendran S; Konishi I; Matsumura N; Cohn DE; Selvendiran K
Int J Cancer; 2017 Nov; 141(9):1856-1866. PubMed ID: 28646535
[TBL] [Abstract][Full Text] [Related]
17. A novel tumor-promoting mechanism of IL6 and the therapeutic efficacy of tocilizumab: Hypoxia-induced IL6 is a potent autophagy initiator in glioblastoma via the p-STAT3-MIR155-3p-CREBRF pathway.
Xue H; Yuan G; Guo X; Liu Q; Zhang J; Gao X; Guo X; Xu S; Li T; Shao Q; Yan S; Li G
Autophagy; 2016 Jul; 12(7):1129-52. PubMed ID: 27163161
[TBL] [Abstract][Full Text] [Related]
18. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway.
Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW
Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447
[TBL] [Abstract][Full Text] [Related]
19. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
[TBL] [Abstract][Full Text] [Related]
20. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
Chaib I; Karachaliou N; Pilotto S; Codony Servat J; Cai X; Li X; Drozdowskyj A; Servat CC; Yang J; Hu C; Cardona AF; Vivanco GL; Vergnenegre A; Sanchez JM; Provencio M; de Marinis F; Passaro A; Carcereny E; Reguart N; Campelo CG; Teixido C; Sperduti I; Rodriguez S; Lazzari C; Verlicchi A; de Aguirre I; Queralt C; Wei J; Estrada R; Puig de la Bellacasa R; Ramirez JL; Jacobson K; Ditzel HJ; Santarpia M; Viteri S; Molina MA; Zhou C; Cao P; Ma PC; Bivona TG; Rosell R
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
